Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial

Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.

Zhitong FinanceMay 16 08:10

Arcellx Is Maintained at Buy by Stifel

Arcellx Is Maintained at Buy by Stifel

Dow JonesMay 15 05:58

Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.

Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.

Zhitong FinanceMay 15 05:50

Stifel Maintains Buy on Arcellx, Raises Price Target to $83

Stifel analyst Benjamin Burnett maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $82 to $83.

BenzingaMay 15 05:47

Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

TipRanksMay 14 09:05

Analyst Expectations For Arcellx's Future

During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, she

BenzingaMay 14 07:01